Rivaroxaban concentration in patientps with deep vein thrombosis who reported thrombus progression or minor hemorrhagic complications: First Polish experience

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 10, 2014, Pages 553-555

  Zalewski, Jarosław ^a   Rychlak, Radoslaw ^a   Góralczyk, Tadeusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ARTICLE; BLEEDING; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; POLISH CITIZEN; PROTHROMBIN TIME; THROMBOEMBOLISM; THROMBOSIS; AGED; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DISEASE COURSE; DOSE RESPONSE; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; POLAND; VENOUS THROMBOSIS;

AGED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POLAND; RIVAROXABAN; VENOUS THROMBOSIS;

EID: 84908488796     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2470     Document Type: Article

References (10)

1. Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res. 2011;127:497-504.
2. Agnelli G, Becattini C, Franco L. New oral anticoagulants for the treatment of venous thromboembolism. Clin Haematol. 2013;26:151-161.
3. Bauersachs R, Berkowitz SD, Büller HR; the EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510.
4. Büller HR, Prins MH, Lensing A W A; the EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-1297.
5. Molenaar PJ, Dinkelaar J, Leyte A. Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med. 2012;50:1799-1807.
6. Lindhoff-Last E, Samama MM, Ortel TL, et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010;32:673-679.
7. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133-139.
8. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756-760.
9. Tripodi A, Di Iorio G, Lippi G, et al. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1). Clin Chem Lab Med. 2012;50:2137-2140.
10. Undas A, Pasierski T, Windyga J, Crowther M. Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn. 2014;124:124-135.